102-06-7

应用筛选条件

关键词:'102-06-7'

显示 1-3 共 3 条结果关于 "102-06-7" 范围论文

Dermal absorption and disposition of 1,3-diphenylguanidine in rats.

P V Shah et al.

Journal of toxicology and environmental health, 15(5), 623-633 (1985-01-01)

Dermal absorption, distribution, and metabolism of 1,3-diphenylguanidine (CAS 102-06-7) (DPG), widely used as an accelerator in processing rubber and in food packaging, was studied in adult female Sprague-Dawley rats. DPG shows 10% penetration through clipped back skin of the rats

Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial.

Rachel S Kerr et al.

The Lancet. Oncology, 17(11), 1543-1557 (2016-09-24)

Antiangiogenic agents have established efficacy in the treatment of metastatic colorectal cancer. We investigated whether bevacizumab could improve disease-free survival in the adjuvant setting after resection of the primary tumour. For the open-label, randomised, controlled QUASAR 2 trial, which was

Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial.

Victor Kande Betu Ku Mesu et al.

Lancet (London, England), 391(10116), 144-154 (2017-11-09)

Few therapeutic options are available to treat the late-stage of human African trypanosomiasis, a neglected tropical disease, caused by Trypanosoma brucei gambiense (g-HAT). The firstline treatment is a combination therapy of oral nifurtimox and intravenous eflornithine that needs to be

1/1